Home » Overview of Spider Vein Treatment » Questions to Ask Your Doctor

Questions to Ask your Doctor

Before undergoing any medical procedure, it’s important to make sure you’re knowledgeable about the procedure and comfortable with the physician performing the procedure.  You should tell your doctor about any medical conditions you have and any medications that you are taking.  Here is a list of common questions to ask your doctor during your consultation for vein treatment:

  • What is causing my symptoms?
  • What kind of tests do you recommend and why?
  • What self-care steps can I take to treat my condition conservatively?
  • If those don’t work, what is the best course of action for me?
  • What treatments are available?
  • I have other health issues. How do they impact treatment options for my varicose or spider veins?
  • Are there any restrictions that I should follow?
  • Do you recommend that I see a specialist?
  • Do you have any printed materials that I can take home? Can you recommend a website where I can get more information?
  • How many spider vein procedures do you perform each year?
  • Of that total, what percentage is sclerotherapy?
  • What has been your experience using sclerotherapy in patients?
  • What type of sclerosing agent do you use?
  • Is it FDA approved?
  • What results can I expect from the treatment?
  • What are possible side effects of the treatment?
  • How many sessions do you anticipate I will need? How long is each session?
  • Will the procedure be covered by insurance?
Remember, being well-informed is the first step to ensuring an optimal outcome. Don’t hesitate to ask questions during your appointment if you don’t understand something.

Important Safety Information for Sotradecol® Injection
Sotradecol is contraindicated in patients with previous hypersensitivity to the drug; inflammation or incompetence of superficial or deep veins; phlebitis migrans; acute cellulitis; allergic conditions; acute infections; varicosities caused by abdominal and pelvic tumors unless the tumor has been removed; bedridden patients; diabetes; toxic hyperthyroidism; tuberculosis; asthma; neoplasm; sepsis; blood dyscrasias; and acute respiratory or skin diseases.

Due to the risk of deep vein thrombosis, patients should be evaluated for valvular competency and deep venous patency before treatment and slow injections of a small volume (< 2 mL) should be injected. Patients should be monitored post-treatment for deep vein thrombosis and pulmonary embolism. Extreme caution must be exercised in the presence of underlying arterial disease.

Severe adverse local effects, including tissue necrosis, may occur following extravasation; therefore, take care in intravenous needle placement and use the smallest effective volume at each injection site.

Allergic reactions, including fatal anaphylaxis, have been reported. As a precaution, it is recommended that 0.5 mL of Sotradecol be injected, followed by observation for several hours before administration of a second or larger dose. Emergency resuscitation equipment should be immediately available, and the physician prepared to treat an anaphylactic reaction.

At least 6 deaths have been reported. Four of the deaths were cases of anaphylaxis; one in a patient with a history of asthma, a contraindication to Sotradecol use. Another death was in a patient who was taking an antiovulatory agent. One death (pulmonary embolism) occurred in a patient not taking an antiovulatory agent, treated with sodium tetradecyl acetate. Other adverse reactions reported include pulmonary embolism; local injection site reactions (pain, urticaria, ulceration); permanent discoloration of sclerosed vein segment; sloughing and necrosis of tissue following extravasation of the drug; allergic reactions (hives, asthma, hayfever); headache; nausea; and vomiting.

Please see full Prescribing Information for more information here.